Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), incorporated in Ireland, filed this Current Report on November 10, 2021. The filing announces the release of earnings results for the third quarter ended October 2, 2021. The company operates in the pharmaceutical and consumer health sectors.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures rather than reporting the results directly.
The company utilizes non-GAAP measures to evaluate ongoing operating trends. These measures exclude items such as:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Restructuring charges and termination benefits.
- Impairment charges and unusual litigation costs.
- Foreign currency translation movements.
- Net sales from specific acquisitions (e.g., Dr. Fresh, Eastern European Brands) to calculate organic growth.
Material Changes and Adjustments
The filing details the specific adjustments applied to GAAP results to derive non-GAAP figures for the three and nine months ended October 2, 2021, compared to the prior year periods. Notable adjustments for the current period include a "Net SPA arbitration settlement award" and "Eastern European Brands acquisition net sales." The prior year period included adjustments for "Loss on early debt extinguishment" and "Rosemont Pharmaceuticals business net sales."
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, numerical outlooks, or detailed risk factors. Management commentary indicates that non-GAAP measures are used for planning, forecasting, and determining compensation. The company emphasizes that these supplemental measures should be considered in conjunction with, not in lieu of, GAAP financial statements.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific revenue, earnings per share, and margin figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures in the full earnings release.
- Assess the impact of the "Net SPA arbitration settlement award" on net income.
- Confirm the organic net sales growth rate excluding the impact of the Dr. Fresh and Eastern European Brands acquisitions.
- Examine the full 10-Q or 10-K for detailed debt levels and liquidity positions not included in this 8-K.